Aerpio Pharmaceuticals Inc

NASDAQ:ARPO   3:59:35 PM EDT
1.57
+0.04 (+2.61%)
Other Pre-Announcement

Aerpio Pharmaceuticals Reports Q3 Loss Per Share $0.12

Published: 11/10/2020 13:13 GMT
Aerpio Pharmaceuticals Inc (ARPO) - Aerpio Reports Third Quarter 2020 Financial Results and Provides Business Update.
Q3 Loss per Share $0.12.
Ended Q3 2020 With $47.3 Million in Cash and Cash Equivalents.
Enrollment Completed in 28-day Phase 2 Razuprotafib Glaucoma Trial.
Data From Phase 2 Razuprotafib Glaucoma Trial Expected to Be Reported in December 2020 Or Possibly in Early January 2021.